8
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      PICK1-Deficient Mice Exhibit Impaired Response to Cocaine and Dysregulated Dopamine Homeostasis

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Protein interacting with C-kinase 1 (PICK1) is a widely expressed scaffold protein known to interact via its PSD-95/discs-large/ZO-1 (PDZ)-domain with several membrane proteins including the dopamine (DA) transporter (DAT), the primary target for cocaine’s reinforcing actions. Here, we establish the importance of PICK1 for behavioral effects observed after both acute and repeated administration of cocaine. In PICK1 knock-out (KO) mice, the acute locomotor response to a single injection of cocaine was markedly attenuated. Moreover, in support of a role for PICK1 in neuroadaptive changes induced by cocaine, we observed diminished cocaine intake in a self-administration paradigm. Reduced behavioral effects of cocaine were not associated with decreased striatal DAT distribution and most likely not caused by the ∼30% reduction in synaptosomal DA uptake observed in PICK1 KO mice. The PICK1 KO mice demonstrated preserved behavioral responses to DA receptor agonists supporting intact downstream DA receptor signaling. Unexpectedly, we found a prominent increase in striatal DA content and levels of striatal tyrosine hydroxylase (TH) in PICK1 KO mice. Chronoamperometric recordings showed enhanced DA release in PICK1 KO mice, consistent with increased striatal DA pools. Viral-mediated knock-down (KD) of PICK1 in cultured dopaminergic neurons increased TH expression, supporting a direct cellular effect of PICK1. In summary, in addition to demonstrating a key role of PICK1 in mediating behavioral effects of cocaine, our data reveal a so far unappreciated role of PICK1 in DA homeostasis that possibly involves negative regulation of striatal TH levels.

          Related collections

          Most cited references59

          • Record: found
          • Abstract: found
          • Article: not found

          Global burden of disease attributable to illicit drug use and dependence: findings from the Global Burden of Disease Study 2010.

          No systematic attempts have been made to estimate the global and regional prevalence of amphetamine, cannabis, cocaine, and opioid dependence, and quantify their burden. We aimed to assess the prevalence and burden of drug dependence, as measured in years of life lived with disability (YLDs), years of life lost (YLLs), and disability-adjusted life years (DALYs). We conducted systematic reviews of the epidemiology of drug dependence, and analysed results with Global Burden of Diseases, Injuries, and Risk Factors Study 2010 (GBD 2010) Bayesian meta-regression technique (DisMod-MR) to estimate population-level prevalence of dependence and use. GBD 2010 calculated new disability weights by use of representative community surveys and an internet-based survey. We combined estimates of dependence with disability weights to calculate prevalent YLDs, YLLs, and DALYs, and estimated YLDs, YLLs, and DALYs attributable to drug use as a risk factor for other health outcomes. Illicit drug dependence directly accounted for 20·0 million DALYs (95% UI 15·3-25·4 million) in 2010, accounting for 0·8% (0·6-1·0) of global all-cause DALYs. Worldwide, more people were dependent on opioids and amphetamines than other drugs. Opioid dependence was the largest contributor to the direct burden of DALYs (9·2 million, 95% UI 7·1-11·4). The proportion of all-cause DALYs attributed to drug dependence was 20 times higher in some regions than others, with an increased proportion of burden in countries with the highest incomes. Injecting drug use as a risk factor for HIV accounted for 2·1 million DALYs (95% UI 1·1-3·6 million) and as a risk factor for hepatitis C accounted for 502,000 DALYs (286,000-891,000). Suicide as a risk of amphetamine dependence accounted for 854,000 DALYs (291,000-1,791,000), as a risk of opioid dependence for 671,000 DALYs (329,000-1,730,000), and as a risk of cocaine dependence for 324,000 DALYs (109,000-682,000). Countries with the highest rate of burden (>650 DALYs per 100,000 population) included the USA, UK, Russia, and Australia. Illicit drug use is an important contributor to the global burden of disease. Efficient strategies to reduce disease burden of opioid dependence and injecting drug use, such as delivery of opioid substitution treatment and needle and syringe programmes, are needed to reduce this burden at a population scale. Australian National Health and Medical Research Council, Australian Government Department of Health and Ageing, Bill & Melinda Gates Foundation. Copyright © 2013 Elsevier Ltd. All rights reserved.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Scaffold proteins: hubs for controlling the flow of cellular information.

            The spatial and temporal organization of molecules within a cell is critical for coordinating the many distinct activities carried out by the cell. In an increasing number of biological signaling processes, scaffold proteins have been found to play a central role in physically assembling the relevant molecular components. Although most scaffolds use a simple tethering mechanism to increase the efficiency of interaction between individual partner molecules, these proteins can also exert complex allosteric control over their partners and are themselves the target of regulation. Scaffold proteins offer a simple, flexible strategy for regulating selectivity in pathways, shaping output behaviors, and achieving new responses from preexisting signaling components. As a result, scaffold proteins have been exploited by evolution, pathogens, and cellular engineers to reshape cellular behavior.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              SLC6 neurotransmitter transporters: structure, function, and regulation.

              The neurotransmitter transporters (NTTs) belonging to the solute carrier 6 (SLC6) gene family (also referred to as the neurotransmitter-sodium-symporter family or Na(+)/Cl(-)-dependent transporters) comprise a group of nine sodium- and chloride-dependent plasma membrane transporters for the monoamine neurotransmitters serotonin (5-hydroxytryptamine), dopamine, and norepinephrine, and the amino acid neurotransmitters GABA and glycine. The SLC6 NTTs are widely expressed in the mammalian brain and play an essential role in regulating neurotransmitter signaling and homeostasis by mediating uptake of released neurotransmitters from the extracellular space into neurons and glial cells. The transporters are targets for a wide range of therapeutic drugs used in treatment of psychiatric diseases, including major depression, anxiety disorders, attention deficit hyperactivity disorder and epilepsy. Furthermore, psychostimulants such as cocaine and amphetamines have the SLC6 NTTs as primary targets. Beginning with the determination of a high-resolution structure of a prokaryotic homolog of the mammalian SLC6 transporters in 2005, the understanding of the molecular structure, function, and pharmacology of these proteins has advanced rapidly. Furthermore, intensive efforts have been directed toward understanding the molecular and cellular mechanisms involved in regulation of the activity of this important class of transporters, leading to new methodological developments and important insights. This review provides an update of these advances and their implications for the current understanding of the SLC6 NTTs.
                Bookmark

                Author and article information

                Journal
                eNeuro
                eNeuro
                eneuro
                eneuro
                eNeuro
                eNeuro
                Society for Neuroscience
                2373-2822
                14 May 2018
                11 June 2018
                May-Jun 2018
                : 5
                : 3
                : ENEURO.0422-17.2018
                Affiliations
                [1 ]Molecular Neuropharmacology and Genetics Laboratory, Department of Neuroscience, Faculty of Health and Medical Sciences, University of Copenhagen , Copenhagen DK-2200, Denmark
                [2 ]Laboratory of Neuropsychiatry, Psychiatric Center Copenhagen, Faculty of Health and Medical Sciences, University of Copenhagen , Copenhagen DK-2200, Denmark
                [3 ]Department of Cellular and Integrative Physiology, University of Texas Health Science Center at San Antonio , TX 78229
                Author notes

                The authors declare no competing financial interests.

                Author contributions: K.L.J., G.S., G.W., A.F.-J., K.L.M., L.D., U.G., and M.R. designed research; K.L.J., G.S.,. D.D., W.A.O., T.R.-C., M.B.L., A.H.R., N.R.C., P.W., G.W., and M.R. performed research; K.L.J., G.S., D.D., W.A.O., T.R.-C., M.B.L., A.H.R., N.R.C., P.W., G.W., K.L.M., L.D., U.G., and M.R. analyzed data; K.L.J., G.S., G.W., L.D., U.G., and M.R. wrote the paper.

                This work was supported by the Lundbeck Fondation (M.R.), the Danish Medical Research Council (U.G., M.R., K.L.J.), University of Copenhagen BioScaRT Program of Excellence (G.S., U.G.), Lundbeck Foundation Center for Biomembranes in Nanomedicine (U.G.), the Weimann Foundation (M.R.), and the National Institutes of Health Grant R21 DA038504 (to L.C.D.).

                [*]

                K.L.J. and G.S. contributed equally to this work.

                Correspondence should be addressed to either of the following: Mattias Rickhag, Molecular Neuropharmacology and Genetics Laboratory, Department of Neuroscience, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen DK-2200, Denmark, E-mail: rickhag@ 123456sund.ku.dk ; or Ulrik Gether, Molecular Neuropharmacology and Genetics Laboratory, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen DK-2200, Denmark, E-mail: gether@ 123456Sund.ku.dk .
                Author information
                http://orcid.org/0000-0001-8985-9126
                http://orcid.org/0000-0002-4829-439X
                http://orcid.org/0000-0001-7659-5539
                http://orcid.org/0000-0003-3307-2839
                http://orcid.org/0000-0001-9274-6691
                http://orcid.org/0000-0002-0020-3807
                Article
                eN-NWR-0422-17
                10.1523/ENEURO.0422-17.2018
                6001137
                22e3178d-1dab-4525-a6c3-04bc01262372
                Copyright © 2018 Jensen et al.

                This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license, which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.

                History
                : 5 December 2017
                : 18 April 2018
                : 27 April 2018
                Page count
                Figures: 6, Tables: 2, Equations: 0, References: 68, Pages: 22, Words: 15113
                Funding
                Funded by: Lundbeck Foundation (MR)
                Funded by: Danish Medical Research Council (UG, MR, KLJ)
                Funded by: University of Copenhagen BioScaRT programme (UG, GS)
                Funded by: Lundbeck Foundation Center for Biomembranes in Nanomedicine (UG)
                Funded by: Købmand I Odense Johan og Hanne Weimann Født Seedorffs Legat (MR)
                Funded by: NIH R21 DA038504 (LD)
                Categories
                3
                3.1
                New Research
                Disorders of the Nervous System
                Custom metadata
                May/June 2018

                cocaine,dopamine homeostasis,drug addiction,protein interacting with c-kinase 1,striatum,tyrosine hydroxylase

                Comments

                Comment on this article